Recall events
/
Event 95714
Event summary
Timeline bucket November 04, 2024
Product types Drug
Classifications Class I
Statuses Ongoing
Recalling firm wording Boulla LLC
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
4 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 4
VitalityXtra Capsules, 500 mg, packaged in 10 count blisters in cartons, Distributed by: VitalityXtra, San Francisco, CA www.vitalityxtra.com
D-0083-2025
Recall number D-0083-2025
Initiated November 04, 2024
Classification Class I
Status Ongoing
Quantity Unknown
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.
Code information Lot #: 230811, Exp: 08/11/2025
Distribution pattern Nationwide within the United States
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[739]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 4
PeakMax Capsules, 500 mg, packaged in 10 count blisters in cartons, Distributed by: PeakMax, San Francisco, CA, www.PeakMax.com
D-0084-2025
Recall number D-0084-2025
Initiated November 04, 2024
Classification Class I
Status Ongoing
Quantity Unknown
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.
Code information Lot #: 230811, Exp: 08/11/2025
Distribution pattern Nationwide within the United States
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[764]
FDA event record
· Exact recall-number query on openFDA
drug · product 3 of 4
ZoomMax Capsules, 500 mg, 10 count blisters in cartons, Distributed by: ZoomMax, 2108 N St. Sacramento, CA 95816, www.zoommax.com
D-0085-2025
Recall number D-0085-2025
Initiated November 04, 2024
Classification Class I
Status Ongoing
Quantity Unknown
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.
Code information Lot #: YZM240406, Exp: 04/05/2027
Distribution pattern Nationwide within the United States
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[765]
FDA event record
· Exact recall-number query on openFDA
drug · product 4 of 4
ZapMax Capsules, 500 mg, 10 count blisters in cartons, Distributed by: ZapMax, 2108 N St. Sacramento, CA 95816, www.zapmax.com
D-0086-2025
Recall number D-0086-2025
Initiated November 04, 2024
Classification Class I
Status Ongoing
Quantity Unknown
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.
Code information Lot #: YZM240406, Exp: 04/05/2027
Distribution pattern Nationwide within the United States
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[14908]
FDA event record
· Exact recall-number query on openFDA
